Adaptive Biotechnologies Corp. Hits New 52-Week High of $13.90

Adaptive Biotechnologies Corp. has reached a significant milestone by hitting a new 52-week high of USD 13.90 on September 19, 2025. This achievement marks a remarkable performance over the past year, with the stock soaring 282.81%, significantly outpacing the S&P 500's growth of 16.64% during the same period.
As a small-cap company in the Pharmaceuticals & Biotechnology sector, Adaptive Biotechnologies Corp. has demonstrated resilience and notable activity in the market. With a market capitalization of USD 1,910 million, the company continues to navigate the competitive landscape of its industry.

Despite being a loss-making entity, the stock's impressive price movement reflects investor sentiment and market dynamics. The company's price-to-book ratio stands at 10.63, indicating a premium valuation relative to its book value. Additionally, the debt-to-equity ratio of -0.30 suggests a unique financial structure, while the return on equity is reported at -67.30%.

Overall, Adaptive Biotechnologies Corp.'s recent performance underscores its position within the pharmaceuticals and biotechnology sector, marking a noteworthy achievement in its stock journey.